# Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children

> **NCT01096056** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 40 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza vaccine GSK2186877A formulation 1
- **BIOLOGICAL:** Influenza vaccine GSK2186877A formulation 2
- **BIOLOGICAL:** Fluarix

## Key facts

- **NCT ID:** NCT01096056
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-05
- **Primary completion:** 2010-12-13
- **Final completion:** 2010-12-13
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01096056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01096056, "Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01096056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*